Skip to main content

Table 3 Multivariate analysis for GVHD

From: Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

  Acute GVHD II–IV Acute GVHD III–IV Chronic GVHD Ext. chronic GVHD
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
ATG vs PTCY 0.98 (0.66–1.46) 0.93 0.84 (0.42–1.71) 0.64 1.22 (0.79–1.87) 0.37 0.64 (0.37–1.09) 0.09
Age (per 10 years) 1 (0.91–1.09) 0.92 1.01 (0.86–1.18) 0.92 1.06 (0.97–1.16) 0.20 1.03 (0.89–1.18) 0.73
sec. AML vs de novo 1.23 (0.95–1.61) 0.12 1.26 (0.79–2) 0.34 1.01 (0.76–1.33) 0.96 1.62 (1.1–2.39) 0.01
Adverse cytogenetics vs other 0.94 (0.74–1.21) 0.65 1.12 (0.73–1.71) 0.60 0.73 (0.56–0.96) 0.03 0.61 (0.39–0.95) 0.03
Female donor-male recipient vs other 1.27 (0.96–1.68) 0.10 1.67 (1.05–2.66) 0.03 1.07 (0.79–1.45) 0.65 1.05 (0.66–1.67) 0.83
RIC vs MAC 0.79 (0.62–1) 0.046 0.89 (0.59–1.36) 0.60 0.97 (0.76–1.23) 0.79 0.78 (0.54–1.14) 0.20
KPS ≥ 90 0.83 (0.65–1.06) 0.13 0.64 (0.42–0.97) 0.03 0.91 (0.71–1.17) 0.45 0.92 (0.63–1.34) 0.67
Patient CMV positivity 1.05 (0.85–1.31) 0.64 1.01 (0.68–1.48) 0.98 1.28 (1.03–1.6) 0.03 1.05 (0.75–1.47) 0.77
Donor CMV positivity 1 (0.81–1.23) 0.99 1.06 (0.73–1.53) 0.77 0.97 (0.79–1.2) 0.80 1.32 (0.96–1.82) 0.09
Year of transplantation 1.01 (0.96–1.06) 0.75 1.03 (0.94–1.12) 0.57 1 (0.95–1.05) 0.94 1.07 (0.99–1.16) 0.09
PBSC vs BM 1.05 (0.75–1.47) 0.77 1.1 (0.6–2) 0.76 1.1 (0.78–1.55) 0.59 1.37 (0.79–2.4) 0.26
  1. Abbreviations: aGVHD acute graft-versus-host disease, AML acute myeloid leukemia, ATG antithymocyte globulin, BM bone marrow, CI confidence interval, CMV cytomegalovirus, cGVHD chronic graft-versus-host disease, Ext extensive, HR hazard ratio, KPS Karnofsky Performance Status, MAC myeloablative conditioning regimen, PBSC peripheral blood stem cells, PTCY post-transplantation cyclophosphamide, RIC reduced intensity conditioning regimen, sec. AML secondary acute myeloid leukemia